DrugPatentWatch Database Preview
Hq Spclt Pharma Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for HQ SPCLT PHARMA, and when can generic versions of HQ SPCLT PHARMA drugs launch?
HQ SPCLT PHARMA has ten approved drugs.
There are eight US patents protecting HQ SPCLT PHARMA drugs.
There are forty-seven patent family members on HQ SPCLT PHARMA drugs in twenty-five countries and sixty-nine supplementary protection certificates in fourteen countries.
Summary for Hq Spclt Pharma
| International Patents: | 47 |
| US Patents: | 8 |
| Tradenames: | 13 |
| Ingredients: | 9 |
| NDAs: | 10 |
Drugs and US Patents for Hq Spclt Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hq Spclt Pharma | MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER | magnesium sulfate | INJECTABLE;INJECTION | 207349-001 | Mar 2, 2016 | AP | RX | No | No | Start Trial | Start Trial | ||||
| Hq Spclt Pharma | MAGNESIUM SULFATE IN PLASTIC CONTAINER | magnesium sulfate | INJECTABLE;INJECTION | 207350-003 | Dec 6, 2017 | AP | RX | No | No | Start Trial | Start Trial | ||||
| Hq Spclt Pharma | DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | SOLUTION;INTRAVENOUS | 206628-004 | Jun 22, 2018 | RX | Yes | No | 9,649,296 | Start Trial | Y | Start Trial | |||
| Hq Spclt Pharma | LINEZOLID | linezolid | SOLUTION;INTRAVENOUS | 207001-001 | Jul 7, 2017 | AP | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hq Spclt Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hq Spclt Pharma | PLATINOL | cisplatin | INJECTABLE;INJECTION | 018057-002 | Approved Prior to Jan 1, 1982 | 4,177,263 | Start Trial |
| Hq Spclt Pharma | CISPLATIN | cisplatin | INJECTABLE;INJECTION | 018057-004 | Nov 8, 1988 | 4,177,263 | Start Trial |
| Hq Spclt Pharma | PLATINOL-AQ | cisplatin | INJECTABLE;INJECTION | 018057-003 | Jul 18, 1984 | 4,310,515 | Start Trial |
| Hq Spclt Pharma | PLATINOL-AQ | cisplatin | INJECTABLE;INJECTION | 018057-003 | Jul 18, 1984 | 5,562,925 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Hq Spclt Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Argentina | 098013 | Start Trial |
| South Korea | 20020093839 | Start Trial |
| Mexico | PA03006229 | Start Trial |
| Slovakia | 12782002 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hq Spclt Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0961612 | CA 2009 00036 | Denmark | Start Trial | PRODUCT NAME: PACLITAXELALBUMIN |
| 0984957 | CR 2012 00035 | Denmark | Start Trial | PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105 |
| 1853250 | 122014000065 | Germany | Start Trial | PRODUCT NAME: PACLITAXEL ALS AN ALBUMIN GEBUNDENE NANOPARTIKEL-FORMULIERUNG; REGISTRATION NO/DATE: K(2013)9835 20131220 |
| 1499331 | 122014000007 | Germany | Start Trial | PRODUCT NAME: NATRIUMSULFAT, MAGNESIUMSULFAT UND KALIUMSULFAT; NAT. REGISTRATION NO/DATE: 86203.00.00 20130808; FIRST REGISTRATION: BELGIEN BE434323 20130220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
